Need Help? Contact Us.

Enquire now

Cartilage

IDS provides highly accurate assays to support measurement of cartilage degradation markers in samples from animal models.

Cartilage degradation markers for use in Translational Research

Cartilage is tough but flexible connective tissue found in many areas of the body such as joints between bones, between vertebrae in the spine, ears and nose. Cartilage is made up of type II collagen, proteoglycans, non-collagenous proteins and water. The non-collagenous proteins bind to the collagen to form a mesh which attracts water. This combination of components gives the cartilage its strength but also its flexibility.

It has been suggested that measurement of markers of cartilage degradation may provide identification of cartilage damage at an earlier stage a more dynamic assessment of damage allowing rapid feedback of efficacy of treatment.

Studies have indicated clear elevations of biomarkers of cartilage degradation in the presence of certain diseases. Furthermore, measurements of CTX-II in patients with osteoarthritis have been found to correlate with radiological measurements of structural damage1. Measurements of CTX-II have also been shown to correlate with radiological progression of diseases such as osteoarthritis and rheumatoid arthritis2-5.

Many potential biomarkers of arthritis show clear elevation in the presence of the disease.  However, the levels of these markers often overlap with healthy controls and only few correlate to radiologically confirmed joint damage, making their use in a clinical setting problematic.  However, it may be that different biomarkers are appropriate in specific disease states, without a single biomarker being suitable for all

  1. Mouritzen U, Christgau S, Lehmann H-J, Tankó L B, Christiansen C.  Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index.  Ann Rheum Dis 2003;62:332–336
  2. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E.  Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage.  Ann Rheum Dis 2001;60:619–26.
  3. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD.  Baseline levels of urinary glucosyl-galactosyl pyridinoline and type II collagen C-telopeptide are associated with progression of joint destruction in patients with early rheumatoid arthritis.  Arthritis Rheum 2002;46:21–30.
  4. Christgau S, Garnero P, Fledelins C, Moniz C, Ensig M, Gineyts E, et al.  Collagen type II degradation products in urine as an index of cartilage degradation.  Bone 2001;29:209–15.
  5. Garnero P, Ayral X, Rousseau J-C, Christgau S, Sandell L, Delmas PD, et al.  Uncoupling of type II collagen metabolism predicts progression of joint damage in patients with knee osteoarthritis.  Arthritis Rheum 2002;46:2613–24.

Cartilage Products

Filter Products

Type

Portfolio

Panel

Platform

Certification

Assays Certification Platform Clinical Area Portfolio RUO/IVD
Serum Pre-Clinical CartiLaps® (CTX-II) EIA Research Use Only Cartilage Animal Research RUO
Urine Pre-Clinical CartiLaps® (CTX-II) EIA Research Use Only Cartilage Animal Research RUO

Filter Products

Portfolio

Certification

Platform

Clinical Area

Ruo/IVD

Unsure? Contact Us.

Enquire now

Need more information? Enquire now.

This site is registered on wpml.org as a development site.